Forte Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Forte Biosciences, Inc. carries a market capitalization of 252.37M, placing it among publicly traded companies globally.
| Market Cap | 252.37M |
| Enterprise Value | N/A |
Share Statistics
Forte Biosciences, Inc. currently has 13.91M shares outstanding.
| Shares Outstanding | 13.91M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.67 |
| P/TBV Ratio | 9.72 |
| P/FCF Ratio | -6.90 |
| P/OCF Ratio | -6.89 |
Financial Position
Forte Biosciences, Inc. maintains a current ratio of 2.75, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.75 |
| Quick Ratio | 2.49 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -132.29 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 373,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Forte Biosciences, Inc.'s stock has gained approximately 90.31414% over the past 52 weeks. The 50-day moving average sits at 26.20, while the 200-day moving average is 21.98.
| Beta (5Y) | N/A |
| 52-Week Price Change | 90.31414% |
| 50-Day Moving Average | 26.20 |
| 200-Day Moving Average | 21.98 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -76.90M, while operating income came in at -76.97M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -76.97M |
| Pretax Income | -74.44M |
| Net Income | -75.85M |
| EBITDA | -76.90M |
| EBIT | -76.97M |
| Earnings Per Share (EPS) | -4.80 |
Balance Sheet
Total book value stands at -245.49M, with working capital of 41.46M providing operational flexibility.
| Cash & Cash Equivalents | 58.22M |
| Total Debt | N/A |
| Net Debt | -58.22M |
| Equity (Book Value) | -245.49M |
| Book Value Per Share | -15.55 |
| Working Capital | 41.46M |
Cash Flow
Forte Biosciences, Inc. produced -59.33M in operating cash flow over the past twelve months. After subtracting -55,000.00 in capital expenditures, free cash flow totaled -59.39M - equivalent to -3.76 per share.
| Operating Cash Flow | -59.33M |
| Capital Expenditures | -55,000.00 |
| Free Cash Flow | -59.39M |
| FCF Per Share | -3.76 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -17.54 |
| FCF Yield | -14.49 |
Stock Splits
Forte Biosciences, Inc.'s most recent stock split took place on August 28, 2024 with a 25:1 split ratio.
| Last Split Date | 8/28/2024 |
| Split Ratio | 25:1 |
Scores
Forte Biosciences, Inc. posts an Altman Z-Score of 1.62, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.62 |